Therapeutics Hormonal Agents

The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor

Govender Y, Avenant C, Verhoog NJ, Ray RM, Grantham NJ, Africander D, Hapgood JP

Published May 19, 2014 PLoS One, 9(5), e96497
DOI 10.1371/journal.pone.0096497 PMID 24840644 PMC PMC4026143

RRM Academy Synopsis

Depo-Provera alone alters inflammation genes in endocervical cells

In endocervical cells grown in the lab, MPA (the hormone in Depo-Provera shots) raised genes that calm inflammation and mostly lowered genes that drive it, acting through the glucocorticoid receptor. NET-A, another injectable birth control drug, and the body's own progesterone did not cause this broad change. MPA raised calming genes and mostly lowered inflammation-driving genes, on its own.

Study at a glance, lab study: Depo-Provera alone alters inflammation genes in endocervical cells
Study at a glance, lab study: Depo-Provera alone alters inflammation genes in endocervical cells. Source: Govender Y et al., 2014, PMID 24840644.

Key Findings

  • MPA turned on two genes that calm inflammation, called GILZ and IκBα, and mostly lowered three genes that drive it: IL-6, IL-8, and RANTES.
  • NET-A and progesterone did not share this pattern. In some conditions, NET-A appeared to raise the activity of inflammation-driving genes instead.
  • Of five hormone receptors tested, only the glucocorticoid receptor was detected as a protein in the cell lines and in primary endocervical cells (lab-grown from donor cells); no progesterone receptor was found.
  • Lowering the glucocorticoid receptor (gene knockdown) reduced MPA's effect on most of these genes. In a related cell line, MPA drew the receptor directly to the genes it was lowering.
  • MPA binds this receptor more tightly than NET-A or natural progesterone, based on earlier lab work by the same authors.

Interpretation

This lab study grew endocervical cells in dishes and tested which genes turned on or off after each hormone. The glucocorticoid receptor drove MPA's distinct effect on these genes. NET-A and progesterone did not share this pattern. Other research has linked MPA use to shifts in certain infection rates. The glucocorticoid receptor offers one way that link could work. Together, the findings support more study of how birth control hormones act on the cervix through receptors other than the progesterone receptor.

RRM Context

NaProTechnology uses the body's own progesterone for cycle support. This study adds a reason why. MPA switched on the glucocorticoid receptor. The body's own progesterone did not do this. Restorative reproductive medicine keeps watching how birth control hormones act on receptors beyond the progesterone receptor.

Abstract

Clinical studies suggest that the injectable contraceptive medroxyprogesterone acetate (MPA) increases susceptibility to infections such as HIV-1, unlike the injectable contraceptive norethisterone enanthate (NET-EN). We investigated the differential effects, molecular mechanism of action and steroid receptor involvement in gene expression by MPA as compared to NET and progesterone (P4) in the End1/E6E7 cell line model for the endocervical epithelium, a key point of entry for pathogens in the female genital mucosa. MPA, unlike NET-acetate (NET-A) and P4, increases mRNA expression of the anti-inflammatory GILZ and IκBα genes. Similarly, MPA unlike NET-A, decreases mRNA expression of the pro-inflammatory IL-6, IL-8 and RANTES genes, and IL-6 and IL-8 protein levels. The predominant steroid receptor expressed in the End1/E6E7 and primary endocervical epithelial cells is the glucocorticoid receptor (GR), and GR knockdown experiments show that the anti-inflammatory effects of MPA are mediated by the GR. Chromatin-immunoprecipitation results suggest that MPA, unlike NET-A and P4, represses pro-inflammatory cytokine gene expression in cervical epithelial cells via a mechanism involving recruitment of the GR to cytokine gene promoters, like the GR agonist dexamethasone. This is at least in part consistent with direct effects on transcription, without a requirement for new protein synthesis. Dose response analysis shows that MPA has a potency of ∼ 24 nM for transactivation of the anti-inflammatory GILZ gene and ∼ 4-20 nM for repression of the pro-inflammatory genes, suggesting that these effects are likely to be relevant at injectable contraceptive doses of MPA. These findings suggest that in the context of the genital mucosa, these GR-mediated glucocorticoid-like effects of MPA in cervical epithelial cells are likely to play a critical role in discriminating between the effects on inflammation caused by different progestins and P4 and hence susceptibility to genital infections, given the predominant expression of the GR in primary endocervical epithelial cells.

Topics

By this author

Related research

Therapeutics › Hormonal Agents › Progesterone and Progestins · Contraception › Adverse Effects › Bone Density Effects · General Gynecology › Infections › Vaginal and Cervical Infections
Yashini Govender, Chanel Avenant, Nicolette J D Verhoog, Roslyn M Ray, Nicholas J Grantham, Donita Africander, Janet P Hapgood
Y Govender, C Avenant, N Verhoog, R Ray, Nick Grantham, N Grantham, D Africander, J Hapgood
PMID 24840644 24840644 DOI 10.1371/journal.pone.0096497 10.1371/journal.pone.0096497 Govender et al. 2014, Govender 2014